DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Isentress (Raltegravir) - Summary

 
 



ISENTRESS SUMMARY

ISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase strand transfer inhibitor.

ISENTRESS [

Registered trademark of MERCK & CO., Inc.
COPYRIGHT © 2007, 2009 MERCK & CO., Inc.
All rights reserved

] is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.

This indication is based on analyses of plasma HIV-1 RNA levels up through 48 weeks in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults and one was conducted in treatment-naïve adults.

The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies].

The safety and efficacy of ISENTRESS have not been established in pediatric patients.


See all Isentress indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Isentress (Raltegravir)

Targeting semen proteins to prevent HIV infection
Source: HIV / AIDS News From Medical News Today [2015.08.18]
Researchers describe two approaches they say could prevent HIV infection by targeting proteins in semen called amyloid fibrils that boost transmission of the virus.

Few gay teenage boys get tested for HIV
Source: HIV / AIDS News From Medical News Today [2015.08.26]
Teens fear being recognized and don't know where to get tested Only one in five gay and bisexual teen boys have been tested for HIV HIV infections are on the rise for young men who...

'Molecular tweezer' targets HIV and prevents semen from promoting infection
Source: Flu / Cold / SARS News From Medical News Today [2015.08.18]
Compound shaped like a tweezer could prove more effective at preventing HIV infection -- and with less side effects -- than other microbicides in developmentAn unprecedented potential "molecular...

more news >>

Published Studies Related to Isentress (Raltegravir)

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). [2012]
Raltegravir as initial HIV therapy was examined in a double-blind study; 160 patients were randomized to raltegravir (400 mg bid after dose-ranging), 38 to efavirenz, both with tenofovir/lamivudine. At week 240, HIV-RNA remained <50 copies per milliliter in 68.8% (raltegravir) versus 63.2% (efavirenz), and CD4 increases were 302 versus 276 cells per microliter, respectively...

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [2011.09]
OBJECTIVES: To assess the sustainable efficacy and safety of a switch from enfuvirtide to raltegravir in patients with multidrug-resistant HIV infection... CONCLUSIONS: In well-suppressed patients with multidrug-resistant HIV infection, a switch from enfuvirtide to raltegravir is generally well tolerated and has sustained antiviral efficacy when combined with a potent background regimen.

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). [2011.07.31]
CONCLUSION: Half of patients previously on a stable EFV preferred to switch to RAL, after double-blind exposure to RAL for 2 weeks. Substitution of EFV by RAL significantly impacted on lipid levels, stress, and anxiety scores.

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. [2011.07.17]
OBJECTIVE: We evaluated the long-term efficacy of raltegravir according to HIV-1 subtype (B and non-B) using data from three phase III studies in treatment-experienced (BENCHMRK-1 and 2) and treatment-naive (STARTMRK) HIV-infected patients... CONCLUSION: In phase III studies in treatment-naive and treatment-experienced patients, raltegravir showed comparable and potent clinical efficacy against B and non-B HIV-1 subtypes.

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. [2011.04.01]
BACKGROUND: Some human immunodeficiency virus (HIV)-infected individuals are not able to achieve a normal CD4(+) T cell count despite prolonged, treatment-mediated viral suppression. We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size... CONCLUSIONS: Low-level viremia is not likely to be a significant cause of suboptimal CD4(+) T cell gains during HIV treatment. CLINICAL TRIALS REGISTRATION: NCT00631449.

more studies >>

Clinical Trials Related to Isentress (Raltegravir)

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients [Completed]
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with immunosuppressive therapy in liver transplant recipients.

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers [Completed]
The purpose of this study is to characterize the way the first commercially available integrase inhibitor, raltegravir, a new class of antiretrovirals that is used to treat HIV, is distributed into the rectal mucosal tissue. This information will generate important information regarding the drug's penetration into lymphoid tissues that are rapidly depleted in HIV infection. Subsequently strategies to prevent the sexual transmission of HIV and for treating HIV-infected individuals will be designed.

The Effect of Rifapentine on Raltegravir [Completed]

Effect of Antacids on the Pharmacokinetics of Raltegravir [Completed]
The purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men [Completed]
The use of anti-HIV drugs following a potential sexual or injecting drug use exposure to HIV in order to try and prevent an exposure from becoming an infection is common. This is called nonoccupational postexposure prophylaxis (NPEP). The likelihood of NPEP succeeding is related to intrinsic qualities of the drugs used which includes at which point in the life cycle of the HIV virus the drugs work, how strong the drugs are against HIV, and how well tolerated the drugs are i. e. what side effects they produce. Many people skip doses during their treatment or abandon their treatment because of side effects. The anti-HIV drug raltegravir works early in the life cycle of the virus i. e. before it integrates with human DNA, is potent against HIV and causes few side effects. These qualities make it an obvious choice for use as a NPEP treatment. In this study 100 HIV negative men will receive raltegravir along with another HIV drug called truvada (commonly used in NPEP) for 28 days after a possible sexual exposure to HIV. They will be monitored closely for adverse events, side effects and for their ability to take the medicine each day for the whole 28 days. The hypothesis in this study states that raltegravir use in NPEP will be safe, well tolerated and result in a high treatment completion rate.

more trials >>

Reports of Suspected Isentress (Raltegravir) Side Effects

Foetal Exposure During Pregnancy (47)Death (38)Maternal Exposure During Pregnancy (36)Anaemia (26)Pyrexia (24)Depression (21)Pneumonia (19)Cytolytic Hepatitis (19)Rash (19)Eosinophilia (19)more >>


Page last updated: 2015-08-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015